Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8845705 | 0.81 | PNP (0.44) | PNPUSP2TSHREDNRAHTR2A | |
| SCHEMBL8845431 | 0.75 | PNP (0.39) | PNPUSP2TSHREDNRAHTR2A | |
| SCHEMBL18890917 | 0.75 | PNP (0.41) | PNPUSP2TSHREDNRAHTR2A | |
| SCHEMBL14612879 | 0.72 | EP300 (0.40) | PNPUSP2TSHREDNRAHTR2A | |
| SCHEMBL8845687 | 0.72 | FGFR1 (0.47) | PNPUSP2TSHREDNRAHTR2A | |
| Phosphoric Acid SCHEMBL9369722 | 0.71 | PNP (0.37) | PNPUSP2TSHREDNRAHTR2A | |
| SCHEMBL8845576 | 0.69 | USP2 (0.33) | PNPUSP2TSHREDNRAHTR2A | |
| SCHEMBL19242440 | 0.69 | EP300 (0.44) | — | |
| SCHEMBL12741705 | 0.69 | EP300 (0.40) | PNPUSP2TSHREDNRAHTR2A | |
| SCHEMBL12741713 | 0.69 | EP300 (0.42) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160184459-A1 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184459-A1 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE | OR10J3, CCR3, GPR3 | PNP 4354/4885USP2 4120/4885TSHR 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.